MarginsXMarginsX
Home › Markets › Health Care › EXEL

Exelixis Inc. (EXEL)

EXEL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$67.10
-2.75% on the day
Market cap
$16.4B
Large cap
Revenue · 2025
$2.3B
+7.0% on 2024
Net income · 2025
$782.6M
33.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-01-02, https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/0000939767-26-000021-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-01-02.

Profile

FieldValue
TickerEXEL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2000
SEC CIK0000939767
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$2.3B
Net income$782.6M
Operating income$872.2M
Net margin33.7%
Operating margin37.6%
Revenue growth+7.0%
Cash$482.5M
Total assets$2.8B
P/E (computed)20.9×
P/S (computed)7.1×

Warning signs

Cash runway
Cash-flow positive
$304.8M cash at October 2, 2026
Share count, 1 year
-9.0%
2025-10-27 to 2026-10-19 · -21.5% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$41.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$304.8M cash; operating cash flow $293.3M a quarter.Report 2026-10-02
Shares outstanding244,010,895 (2026-10-19); 268,112,157 a year earlier; 310,974,113 three years earlier.Cover page 2026-10-19
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-02-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.2M, sold $42.2M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-10-02
$658.7M$218.1M$280.0M$304.8MNo debt tags$2.5B10-Q 2026-10-29
Q2 2026
2026-07-03
$628.7M$212.1M$307.7M$281.4MNo debt tags$2.4B10-Q 2026-08-05
Q1 2026
2026-04-03
$610.8M$210.5M$251.8M$226.2MNo debt tags$2.4B10-Q 2026-05-05
Q4 2025
2026-01-02
$598.7M$244.5M$333.5M$482.5MNo debt tags$2.3B10-K 2026-02-10
Q3 2025
2025-10-03
$597.8M$193.6M$290.3M$376.3MNo debt tags$2.3B10-Q 2026-10-29
Q2 2025
2025-07-04
$568.3M$184.8M$49.0M$164.4MNo debt tags$2.2B10-Q 2026-08-05
Q1 2025
2025-04-04
$555.4M$159.6M$211.4M$183.8MNo debt tags$2.3B10-Q 2026-05-05
Q4 2024
2025-01-03
$566.8M$139.9M$240.3M$217.4MNo debt tags$2.2B10-K 2026-02-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest annual report10-K2026-02-10
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-10-29
Latest proxyDEFA14A2026-04-17

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.8%
1 month+15.9%
3 months+36.3%
Year to date+57.4%
1 year+62.9%
From 52-week high-5.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
NBIXNeurocrine Biosciences Inc.$165.31-1.25%$16.7B
BNTXBioNTech SE American Depositary Share$85.26-0.40%$21.4B
TECHBio-Techne Corp$72.79-0.01%$11.4B
HALOHalozyme Therapeutics Inc.$96.50-3.76%$11.0B
KYMRKymera Therapeutics Inc.$125.85-1.35%$10.7B
RGENRepligen Corporation$162.78-2.99%$10.4B
QGENQiagen N.V. Common Shares$49.81-0.16%$10.3B
PCVXVaxcyte Inc.$61.61-2.78%$9.8B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier